Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

2 terminated/withdrawn out of 12 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

50%

6 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
6(50.0%)
N/A
2(16.7%)
Phase 2
2(16.7%)
Phase 1
2(16.7%)
12Total
Phase 3(6)
N/A(2)
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT06563895Phase 3Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Role: lead

NCT06469372Not ApplicableCompleted

Cardiac Amyloidosis Discovery Trial

Role: collaborator

NCT04988386Phase 3Active Not Recruiting

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Role: lead

NCT07116473Phase 3Not Yet Recruiting

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Role: lead

NCT03536767Phase 2Active Not Recruiting

Open-Label Study of AG10 in Patients with Cardiomyopathy

Role: lead

NCT05577819Not ApplicableRecruiting

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Role: collaborator

NCT04769479Phase 1Completed

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

Role: lead

NCT04418024Phase 3Withdrawn

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Role: lead

NCT04882735Phase 3Withdrawn

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Role: lead

NCT03294707Phase 1Completed

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Role: lead

NCT03860935Phase 3Completed

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Role: lead

NCT03458130Phase 2Completed

Study of AG10 in Amyloid Cardiomyopathy

Role: lead

All 12 trials loaded